Indicia Production Acquires METIS Biotechnologies

Article

The combined company’s turnover is estimated to reach €8 million ($8.35M) in 2017.

On Jan. 3, 2017 Indicia Production, a contract manufacturer, announced that it will acquire METIS Biotechnologies. METIS develops, produces, and markets rapid microbiological analysis solutions using flow cytometry. Both companies are located in France. The financial terms of the acquisition were not disclosed. Following the acquisition, the consolidated company will operate with 57 employees. Its turnover is estimated to reach €8 million ($8.35M) in 2017, Indicia said.

“The integration of METIS Biotechnologies will strengthen Indicia’s presence on the industrial microbiological control market, in which we have been present since 2008. The technology developed by METIS is now fully operational and meets the needs of the industry,” said Stéphane Legastelois, CEO of Indicia Production in a statement. “In addition, METIS’ know-how in custom solutions will complement our services. This acquisition is part of our strategy to develop through external growth, with a special focus on vertical integration in the field of industrial microbiology.”

Source: Indicia Production

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content